Viatris | VTRS - Ebitda



Viatris reported $1.08B in EBITDA for its fiscal quarter ending in June of 2025.


Ebitda Change Date
Celltrion KRW 221.03B 57.43B Mar/2025
Cspc Pharmaceutical CNY 2.19B 21.88M Dec/2024
Dianthus Therapeutics USD -34828000 2.99M Jun/2025
Divis Laboratories Ltd 7.29B 2.43B Jun/2025
Kangmei Pharma -3262057.35 15.91M Sep/2024
Knight Therapeutics CAD 16.72M 1.05M Sep/2024
Laboratorios Farma EUR 34.94M 102.95M Jun/2025
Malin Corporation EUR -1100000 200K Dec/2024
Medical Developments International AUD 1.78M 3.78M Dec/2024
Neuren Pharmaceuticals AUD 176.7M 166.79M Dec/2024
Organigram Holdings CAD 2.68M 18.86M Jun/2025
Pharma Mar EUR 26.15M 27.2M Jun/2025
Qiagen NV USD 208.98M 38.23M Jun/2025
Sartorius EUR 264.3M 1.3M Jun/2025
Sino Biopharmaceutical CNY 2.59B 1.57B Dec/2024
Tilray USD -101000 2.32M Nov/2024
Viatris USD 1.08B 218.1M Jun/2025
Zhangzhou Pientzehuang Pharmaceutical 1.19B 829.65M Mar/2025